|NASDAQ: GNPX||Healthcare / Biotechnology / USA|
|0.9099||+0.0069||+0.76%||Vol 128.97K||1Y Perf -60.04%|
|Mar 31st, 2023 16:00 DELAYED|
|- -||-0.06 -6.58%|
|Target Price||5.00||Analyst Rating||Strong Buy 1.00|
|Potential %||449.51||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||9.00||Earnings Rating||Neutral|
|Market Cap||47.29M||Earnings Date||29th Mar 2023|
Today's Price Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||124.28K|
|Avg. Monthly Volume||287.37K|
|Avg. Quarterly Volume||401.84K|
Genprex Inc. (NASDAQ: GNPX) stock closed at 0.9099 per share at the end of the most recent trading day (a 0.76% change compared to the prior day closing price) with a volume of 128.97K shares and market capitalization of 47.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Genprex Inc. CEO is J. Rodney Varner.
The one-year performance of Genprex Inc. stock is -60.04%, while year-to-date (YTD) performance is -37.25%. GNPX stock has a five-year performance of -80.64%. Its 52-week range is between 0.7358 and 2.67, which gives GNPX stock a 52-week price range ratio of 9.00%
Genprex Inc. currently has a PE ratio of -3.00, a price-to-book (PB) ratio of 2.50, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -59.41%, a ROC of -62.47% and a ROE of -62.37%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Genprex Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Genprex Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Genprex Inc. is Strong Buy (1), with a target price of $5, which is +449.51% compared to the current price. The earnings rating for Genprex Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Genprex Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Genprex Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.15, ATR14 : 0.09, CCI20 : 1.38, Chaikin Money Flow : -0.22, MACD : -0.10, Money Flow Index : 32.67, ROC : 10.01, RSI : 40.32, STOCH (14,3) : 77.62, STOCH RSI : 0.84, UO : 55.58, Williams %R : -22.38), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Genprex Inc. in the last 12-months were: Ryan M. Confer (Option Excercise at a value of $1 755)
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||-|
Genprex Inc is a clinical stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.
CEO: J. Rodney Varner
Telephone: (877) 774-4679
Address: 1601 Trinity Street, Building B, Austin 78712-1885, TX, US
Number of employees: 8
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.